Effect of Valacyclovir in the Reduction of HSV-2 Recurrence and Shedding

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT00803543
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
19 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Valacyclovir — DRUG
    500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
  • Placebo — DRUG
    Dosage: Two tablets once a day for 24 weeks

Study Details

The purpose of the study is to determine how common herpes is among persons with HIV who do not know they have it and if valacyclovir reduces outbreaks of herpes, the amount of HIV in the blood, and the amount of HSV in bodily secretions.

Key Dates

Start date
Jan 31, 2009
Status verified
Jun 2017
Primary completion
Apr 30, 2014
Completion
Apr 30, 2014

Study Design

Enrollment
103 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Valacyclovir
    This is the arm taking Valacyclovir
  • Placebo Comparator: Placebo
    This is the arm taking the placebo

Primary Outcome Measure

Herpes Simplex Virus Type 2 Recurrence [ Time Frame: 24 Weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Community Care BuildingBirminghamAlabama35294-

Find similar trials in Birmingham, AL

By condition
HIV
By specialty
Infectious disease
By research site
Community Care Building· Birmingham, AL

Related Studies